Hympavzi▼ (marstacimab) – PATIENT CARD

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Carry this card with you at all times. SHOW THIS CARD to any healthcare professional involved in your care and if you go to the emergency room.

IMPORTANT SAFETY INFORMATION FOR PATIENTS RECEIVING TREATMENT WITH HYMPAVZI (marstacimab)

What is the most important information I should know about Hympavzi (marstacimab)?

Hympavzi (marstacimab) is intended for routine prophylaxis treatment of bleeding episodes in patients aged 12 years of age and older, weighing at least 35 kg, who have severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors or severe haemophilia B (congenital factor IX deficiency, FIX <1%) without factor IX inhibitors. Hympavzi (marstacimab) increases how easily your blood clots. Hympavzi (marstacimab) and similar medicines to Hympavzi (marstacimab) have been known to cause blood clots (thrombosis) in the blood vessels, and if the blood clot breaks loose it can travel through the bloodstream, causing an obstruction in another blood vessel (so-called thromboembolic event). Depending on location and severity, thromboembolic events may be life-threatening or fatal.

+ IMPORTANT SAFETY INFORMATION

FOR THE PATIENT

STOP using Hympavzi (marstacimab) and talk to a doctor immediately if you notice any of these symptoms of a possible blood clot including the following side effects:	
• **Swelling or pain in arms or legs** • **Redness or discoloration in arms or legs** • **Shortness of breath** • **Pain in chest or upper back**	• **Fast Heart Rate** • **Numbness in your face** • **Headache** • **Eye pain or swelling**

• **Feeling faint**	• **Trouble seeing** • **Coughing up blood**

IMPORTANT TO REMEMBER: If you have **any** of these symptoms stop using Hympavzi (marstacimab) and call your doctor or seek emergency medical attention right away! These are not all of the symptoms of a possible blood clot. Tell your doctor if you have any symptoms that bother you or do not go away.

INFORMATION ON THE PATIENT AND TREATING PHYSICIAN.

Your treating physician should complete the Patient identification information, drug and treatment information, and provide the treating physician's contact information for you. Always carry this card with you and show it to medical staff in case of emergency.

Name of the patient:

Start date of Hympavzi treatment:

Emergency contact name:

Emergency contact details:

Prescriber name:

Prescriber contact details:

Reporting of side effects

If you notice any side effects, contact your doctor or health care professional. This also applies to side effects that are not described in this patient card.

Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Malta Medicines Authority ADR reporting form, which is available online at http://www.medicinesauthority.gov.mt/adrportal, and sent by post or email to;

P: Pharmacovigilance Section at Post-Licensing Directorate, Malta Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN 3000

E: postlicensing.medicinesauthority@gov.mt

Alternatively, you may also report such events promptly to Pfizer Hellas Pharmacovigilance Department, contact details: +30 210 67 85 908 and +30 210 67 85 808 (24-hour line), or via the webportal Pfizer Adverse Event Safety Reporting (Pfizersafetyreporting.com), or contact the local representative Vivian Corporation Ltd. Tel. +356 2134 4610/ +356 2258 8600).

By reporting side effects you can help provide more information on the safety of this medicine.